Investors focused on the Medical space have likely heard of Genomic Health , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GHDX and the rest of the Medical group's stocks.

Genomic Health is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GHDX is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for GHDX's full-year earnings has moved 12.39% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Based on the most recent data, GHDX has returned 57.46% so far this year. Meanwhile, stocks in the Medical group have gained about 2.52% on average. This means that Genomic Health is outperforming the sector as a whole this year.

Breaking things down more, GHDX is a member of the Medical - Biomedical and Genetics industry, which includes 281 individual companies and currently sits at #107 in the Zacks Industry Rank. On average, this group has gained an average of 0.59% so far this year, meaning that GHDX is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on GHDX as it attempts to continue its solid performance.